ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Recruiting

Phase 2

ACP-211ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Sponsor:

ACADIA Pharmaceuticals Inc.

Code:

NCT07284667

Conditions

Major Depressive Disorder (MDD)

Depressive Disorder, Treatment-Resistant

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

ACP-211

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-08. This information was provided to ClinicalTrials.gov by ACADIA Pharmaceuticals Inc. on 2026-03-12.